BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 32850403)

  • 1. Resurrection of Oral Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: A Historical Account From Bedside to Bench to Bedside.
    Kumana CR; Mak R; Kwong YL; Gill H
    Front Oncol; 2020; 10():1294. PubMed ID: 32850403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
    Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
    Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A biography of arsenic and medicine in Hong Kong and China.
    Au WY
    Hong Kong Med J; 2011 Dec; 17(6):507-13. PubMed ID: 22147326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside.
    Rojewski MT; Körper S; Schrezenmeier H
    Leuk Lymphoma; 2004 Dec; 45(12):2387-401. PubMed ID: 15621751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study.
    Kwong YL; Au WY; Chim CS; Pang A; Suen C; Liang R
    Am J Hematol; 2001 Apr; 66(4):274-9. PubMed ID: 11279639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies.
    Chen Z; Chen GQ; Shen ZX; Chen SJ; Wang ZY
    Semin Hematol; 2001 Jan; 38(1):26-36. PubMed ID: 11172537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of intracellular arsenic trioxide for therapeutic response in acute promyelocytic leukemia.
    Sahu GR; Jena RK
    Am J Hematol; 2005 Feb; 78(2):113-6. PubMed ID: 15682419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide.
    Au WY; Chim CS; Lie AK; Liang R; Kwong YL
    Br J Haematol; 2002 Apr; 117(1):130-2. PubMed ID: 11918543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.
    Huan SY; Yang CH; Chen YC
    Leuk Lymphoma; 2000 Jul; 38(3-4):283-93. PubMed ID: 10830735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.
    Iland HJ; Collins M; Bradstock K; Supple SG; Catalano A; Hertzberg M; Browett P; Grigg A; Firkin F; Campbell LJ; Hugman A; Reynolds J; Di Iulio J; Tiley C; Taylor K; Filshie R; Seldon M; Taper J; Szer J; Moore J; Bashford J; Seymour JF;
    Lancet Haematol; 2015 Sep; 2(9):e357-66. PubMed ID: 26685769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro exposure of acute promyelocytic leukemia cells to arsenic trioxide (As2O3) induces the solitary expression of CD66c (NCA-50/90), a member of the CEA family.
    Di Noto R; Boccuni P; Costantini S; Dello Russo A; Lo Pardo C; Copia C; Annunziata M; Cimino R; Ferrara F; Del Vecchio L
    Tissue Antigens; 1999 Dec; 54(6):597-602. PubMed ID: 10674975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Oral administration of arsenic trioxide induced molecular remission in relapsed acute promyelocytic leukemia].
    Fukuda M
    Rinsho Ketsueki; 2005 Nov; 46(11):1223-5. PubMed ID: 16440808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance therapy with all-trans retinoic acid and arsenic trioxide improves relapse-free survival in adults with low- to intermediate-risk acute promyelocytic leukemia who have achieved complete remission after consolidation therapy.
    Liang B; Zheng Z; Shi Y; Chen J; Hu X; Qian H; Shen Z; Jiang S; Yu K; Feng J
    Onco Targets Ther; 2017; 10():2305-2313. PubMed ID: 28490888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arsenic trioxide: safety issues and their management.
    Au WY; Kwong YL
    Acta Pharmacol Sin; 2008 Mar; 29(3):296-304. PubMed ID: 18298894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arsenic trioxide (As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice.
    Kinjo K; Kizaki M; Muto A; Fukuchi Y; Umezawa A; Yamato K; Nishihara T; Hata J; Ito M; Ueyama Y; Ikeda Y
    Leukemia; 2000 Mar; 14(3):431-8. PubMed ID: 10720138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism of arsenic trioxide in acute promyelocytic leukemia cells.
    Khaleghian A; Ghaffari SH; Ahmadian S; Alimoghaddam K; Ghavamzadeh A
    J Cell Biochem; 2014 Oct; 115(10):1729-39. PubMed ID: 24819152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Successful treatment of relapsed and refractory acute promyelocytic leukemia with arsenic trioxide (As2O3)].
    Tanaka Y; Komatsu H; Ishii K; Nakamura F; Hayashi T; Sawada H; Ono Y; Imanaka T
    Rinsho Ketsueki; 2000 Apr; 41(4):354-7. PubMed ID: 10846468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells.
    Shao W; Fanelli M; Ferrara FF; Riccioni R; Rosenauer A; Davison K; Lamph WW; Waxman S; Pelicci PG; Lo Coco F; Avvisati G; Testa U; Peschle C; Gambacorti-Passerini C; Nervi C; Miller WH
    J Natl Cancer Inst; 1998 Jan; 90(2):124-33. PubMed ID: 9450572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral arsenic trioxide incorporation into frontline treatment with all-trans retinoic acid and chemotherapy in newly diagnosed acute promyelocytic leukemia: A 5-year prospective study.
    Gill H; Kumana CR; Yim R; Hwang YY; Chan TSY; Yip SF; Lee HKK; Mak V; Lau JSM; Chan CC; Kho B; Wong RSM; Li W; Lin SY; Lau CK; Ip HW; Leung RYY; Lam CCK; Kwong YL
    Cancer; 2019 Sep; 125(17):3001-3012. PubMed ID: 31090936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arsenic trioxide: acute promyelocytic leukemia and beyond.
    Bachleitner-Hofmann T; Kees M; Gisslinger H
    Leuk Lymphoma; 2002 Aug; 43(8):1535-40. PubMed ID: 12400595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.